Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 128

1.

The future of warfarin pharmacogenetics in under-represented minority groups.

Cavallari LH, Perera MA.

Future Cardiol. 2012 Jul;8(4):563-76. doi: 10.2217/fca.12.31. Review.

PMID:
22871196
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.

Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ.

Pharmacogenomics. 2009 Aug;10(8):1243-55. doi: 10.2217/pgs.09.71.

PMID:
19663669
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.

Ramirez AH, Shi Y, Schildcrout JS, Delaney JT, Xu H, Oetjens MT, Zuvich RL, Basford MA, Bowton E, Jiang M, Speltz P, Zink R, Cowan J, Pulley JM, Ritchie MD, Masys DR, Roden DM, Crawford DC, Denny JC.

Pharmacogenomics. 2012 Mar;13(4):407-18. doi: 10.2217/pgs.11.164. Epub 2012 Feb 13.

PMID:
22329724
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.

Perera MA, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Daneshjou R, Pluzhnikov A, Crawford DC, Wang J, Liu N, Tatonetti N, Bourgeois S, Takahashi H, Bradford Y, Burkley BM, Desnick RJ, Halperin JL, Khalifa SI, Langaee TY, Lubitz SA, Nutescu EA, Oetjens M, Shahin MH, Patel SR, Sagreiya H, Tector M, Weck KE, Rieder MJ, Scott SA, Wu AH, Burmester JK, Wadelius M, Deloukas P, Wagner MJ, Mushiroda T, Kubo M, Roden DM, Cox NJ, Altman RB, Klein TE, Nakamura Y, Johnson JA.

Lancet. 2013 Aug 31;382(9894):790-6. doi: 10.1016/S0140-6736(13)60681-9. Epub 2013 Jun 5.

PMID:
23755828
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Factors influencing warfarin dose requirements in African-Americans.

Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH.

Pharmacogenomics. 2007 Nov;8(11):1535-44.

PMID:
18034618
[PubMed - indexed for MEDLINE]
6.

Pharmacogenomics of warfarin dose requirements in Hispanics.

Cavallari LH, Momary KM, Patel SR, Shapiro NL, Nutescu E, Viana MA.

Blood Cells Mol Dis. 2011 Feb 15;46(2):147-50. doi: 10.1016/j.bcmd.2010.11.005. Epub 2010 Dec 24.

PMID:
21185752
[PubMed - indexed for MEDLINE]
7.

Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.

Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ.

Pharmacogenomics. 2010 Jun;11(6):781-91. doi: 10.2217/pgs.10.49.

PMID:
20504253
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing.

Chan SL, Suo C, Chia KS, Teo YY.

Pharmacogenomics. 2012 Aug;13(11):1247-56. doi: 10.2217/pgs.12.104.

PMID:
22920395
[PubMed - indexed for MEDLINE]
9.

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

Carlquist JF, Horne BD, Muhlestein JB, Lappé DL, Whiting BM, Kolek MJ, Clarke JL, James BC, Anderson JL.

J Thromb Thrombolysis. 2006 Dec;22(3):191-7.

PMID:
17111199
[PubMed - indexed for MEDLINE]
10.

Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.

Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK, Acton RT.

Pharmacogenomics. 2008 May;9(5):511-26. doi: 10.2217/14622416.9.5.511.

PMID:
18466099
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans.

Schelleman H, Chen J, Chen Z, Christie J, Newcomb CW, Brensinger CM, Price M, Whitehead AS, Kealey C, Thorn CF, Samaha FF, Kimmel SE.

Clin Pharmacol Ther. 2008 Sep;84(3):332-9. doi: 10.1038/clpt.2008.101. Epub 2008 Jul 2.

PMID:
18596683
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians.

Schelleman H, Chen Z, Kealey C, Whitehead AS, Christie J, Price M, Brensinger CM, Newcomb CW, Thorn CF, Samaha FF, Kimmel SE.

Clin Pharmacol Ther. 2007 May;81(5):742-7. Epub 2007 Feb 28.

PMID:
17329985
[PubMed - indexed for MEDLINE]
13.

Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects.

Kadian-Dodov DL, van der Zee SA, Scott SA, Peter I, Martis S, Doheny DO, Rothlauf EB, Lubitz SA, Desnick RJ, Halperin JL.

Vasc Med. 2013 Oct;18(5):290-7. doi: 10.1177/1358863X13503193. Epub 2013 Sep 12.

PMID:
24029542
[PubMed - indexed for MEDLINE]
14.

Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU.

Scott SA, Patel M, Martis S, Lubitz SA, van der Zee S, Yoo C, Edelmann L, Halperin JL, Desnick RJ.

Pharmacogenomics. 2012 Feb;13(3):297-307. doi: 10.2217/pgs.11.156. Epub 2011 Dec 21.

PMID:
22188360
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.

Fung E, Patsopoulos NA, Belknap SM, O'Rourke DJ, Robb JF, Anderson JL, Shworak NW, Moore JH.

Semin Thromb Hemost. 2012 Nov;38(8):893-904. doi: 10.1055/s-0032-1328891. Epub 2012 Oct 6. Review. Erratum in: Semin Thromb Hemost. 2013 Feb;39(1):112.

PMID:
23041981
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

[Possible application of pharmacogenomics to warfarin therapy].

Murata M.

Rinsho Byori. 2011 Jun;59(6):594-7. Review. Japanese.

PMID:
21815482
[PubMed - indexed for MEDLINE]
17.

Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.

Daly AK.

Arch Toxicol. 2013 Mar;87(3):407-20. doi: 10.1007/s00204-013-1013-9. Epub 2013 Feb 2. Review.

PMID:
23376975
[PubMed - indexed for MEDLINE]
18.

The pharmacogenetics of the response to warfarin in Chinese.

Lam MP, Cheung BM.

Br J Clin Pharmacol. 2012 Mar;73(3):340-7. doi: 10.1111/j.1365-2125.2011.04097.x. Review.

PMID:
22023024
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.

Rusdiana T, Araki T, Nakamura T, Subarnas A, Yamamoto K.

Eur J Clin Pharmacol. 2013 Mar;69(3):395-405. doi: 10.1007/s00228-012-1356-9. Epub 2012 Aug 2.

PMID:
22855348
[PubMed - indexed for MEDLINE]
20.

Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans.

Kimmel SE, Christie J, Kealey C, Chen Z, Price M, Thorn CF, Brensinger CM, Newcomb CW, Whitehead AS.

Pharmacogenomics J. 2008 Feb;8(1):53-60. Epub 2007 Feb 27.

PMID:
17325732
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk